Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 12.38 | 7.53 | 34.98 | 13.13 | 18.01 | 8.97 | 14.21 | 12.54 | 15.55 | 13.70 | 13.55 | 22.74 | 12.63 | 29.32 | 18.75 | 10.61 | 23.42 | 26.36 | 19.10 | 14.93 | 8.06 |
| — | -16.0% | +146.2% | +4.7% | +15.8% | -34.5% | +4.9% | -44.8% | +23.1% | -53.3% | -27.7% | +114.2% | -46.0% | +11.3% | -1.8% | -28.9% | +190.7% | -16.3% | -58.3% | — | -86.3% | |
| P/S Ratio | 1.54 | 1.21 | 1.33 | 1.72 | 1.66 | 1.58 | 2.12 | 2.59 | 3.33 | 2.85 | 3.39 | 4.60 | 3.43 | 5.24 | 3.48 | 2.68 | 3.09 | 3.75 | 3.88 | 2.41 | 2.12 |
| — | -23.4% | -37.3% | -33.4% | -50.3% | -44.5% | -37.4% | -43.7% | -2.9% | -45.5% | -2.7% | +71.5% | +11.2% | +39.6% | -10.2% | +11.3% | +45.7% | +52.6% | +76.1% | -3.2% | -24.4% | |
| P/B Ratio | 1.54 | 1.16 | 1.18 | 1.60 | 1.64 | 1.46 | 1.93 | 2.64 | 3.46 | 2.92 | 3.46 | 5.13 | 4.17 | 5.18 | 3.55 | 2.74 | 2.94 | 3.71 | 3.89 | 2.62 | 2.21 |
| — | -20.4% | -38.9% | -39.3% | -52.7% | -50.0% | -44.4% | -48.5% | -17.0% | -43.7% | -2.5% | +87.1% | +41.9% | +39.7% | -8.7% | +4.7% | +32.9% | +73.5% | +93.4% | +22.9% | +6.6% | |
| P/FCF | 9.14 | 5.22 | 5.94 | 12.84 | 6.72 | 11.04 | 14.83 | 29.09 | 13.63 | 8.25 | 12.52 | 56.84 | 11.45 | 16.63 | 15.77 | 40.63 | 25.14 | — | 10.45 | 8.68 | — |
| — | -52.7% | -60.0% | -55.9% | -50.7% | +33.8% | +18.5% | -48.8% | +19.0% | -50.4% | -20.6% | +39.9% | -54.4% | — | +50.8% | +367.9% | — | — | -29.9% | -72.5% | — | |
| EV / EBITDA | 7.83 | 7.51 | 11.83 | 8.47 | 10.84 | 6.73 | 9.12 | 10.17 | 10.33 | 9.06 | 11.11 | 13.86 | 8.36 | 19.52 | 11.47 | 7.71 | 11.69 | 14.13 | 15.83 | 9.29 | 7.59 |
| — | +11.5% | +29.7% | -16.6% | +4.9% | -25.7% | -17.9% | -26.7% | +23.5% | -53.6% | -3.2% | +79.9% | -28.5% | +38.1% | -27.5% | -17.0% | +54.0% | +4.7% | +24.7% | -61.5% | -66.0% | |
| EV / EBIT | 11.36 | 7.51 | 21.46 | 11.34 | 15.39 | 8.62 | 12.89 | 12.07 | 13.58 | 10.67 | 12.31 | 18.50 | 9.33 | 23.55 | 13.79 | 8.35 | 15.43 | 19.00 | 15.30 | 10.47 | 6.22 |
| — | -12.9% | +66.4% | -6.0% | +13.3% | -19.2% | +4.7% | -34.8% | +45.6% | -54.7% | -10.7% | +121.5% | -39.5% | +24.0% | -9.9% | -20.2% | +147.9% | +15.5% | -63.3% | — | -80.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.5% | 50.8% | 41.1% | 46.8% | 51.4% | 49.6% | 50.0% | 46.5% | 54.0% | 52.2% | 50.8% | 54.0% | 60.0% | 49.9% | 52.7% | 52.7% | 48.7% | 51.3% | 46.4% | 46.5% | 45.6% |
| — | +2.5% | -17.8% | +0.7% | -4.8% | -5.0% | -1.6% | -13.9% | -10.1% | +4.5% | -3.7% | +2.4% | +23.3% | -2.7% | +13.7% | +13.3% | +6.8% | +10.1% | +6.3% | +21.1% | +4.3% | |
| Operating Margin | 19.5% | 21.6% | 8.0% | 19.4% | 13.2% | 24.2% | 21.9% | 24.2% | 30.2% | 30.3% | 27.9% | 30.3% | 40.3% | 25.3% | 23.9% | 28.0% | 19.3% | 20.1% | 18.0% | 20.1% | 22.1% |
| — | -10.7% | -63.6% | -19.7% | -56.3% | -20.1% | -21.7% | -20.1% | -24.9% | +19.6% | +17.0% | +8.2% | +108.2% | +25.9% | +33.0% | +39.7% | -12.4% | +93.6% | +79.5% | +568.4% | +423.7% | |
| Net Margin | 13.6% | 16.5% | 3.8% | 13.3% | 9.0% | 17.8% | 14.8% | 20.4% | 21.4% | 20.8% | 25.1% | 20.3% | 27.3% | 17.9% | 18.6% | 25.1% | 13.2% | 14.0% | 20.1% | 16.3% | 26.3% |
| — | -7.2% | -74.7% | -34.5% | -57.8% | -14.5% | -41.0% | +0.2% | -21.5% | +16.1% | +35.2% | -19.2% | +106.3% | +27.6% | -7.7% | +53.7% | -49.8% | +83.9% | +311.8% | +349.9% | +460.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.9% | 3.9% | 0.8% | 3.1% | 2.3% | 4.1% | 3.4% | 5.2% | 5.6% | 5.5% | 6.6% | 5.9% | 8.3% | 4.6% | 4.8% | 6.6% | 3.2% | 3.5% | 5.2% | 4.5% | 6.6% |
| — | -4.3% | -75.9% | -40.0% | -59.7% | -24.9% | -48.2% | -11.2% | -32.5% | +19.3% | +36.2% | -10.7% | +163.0% | +29.6% | -7.8% | +45.4% | -52.0% | +109.5% | +367.9% | +423.6% | +650.6% | |
| ROA | 6.1% | 1.8% | 0.4% | 1.5% | 1.1% | 1.9% | 1.6% | 2.4% | 2.7% | 2.5% | 2.8% | 2.4% | 3.4% | 2.4% | 3.4% | 4.6% | 2.2% | 2.4% | 3.5% | 3.0% | 4.5% |
| — | -6.5% | -75.2% | -39.0% | -60.3% | -22.7% | -43.6% | +2.8% | -20.9% | +2.0% | -18.6% | -48.8% | +53.9% | +0.8% | -1.7% | +54.6% | -51.2% | +103.4% | +342.7% | +396.4% | +594.6% | |
| ROIC | 8.4% | 2.4% | 0.8% | 2.1% | 1.6% | 2.6% | 2.3% | 2.8% | 3.7% | 3.7% | 3.2% | 3.8% | 5.5% | 3.8% | 5.3% | 6.1% | 3.9% | 4.4% | 3.9% | 4.3% | 4.4% |
| — | -8.6% | -65.0% | -24.1% | -58.0% | -30.0% | -29.8% | -26.0% | -33.1% | -3.9% | -38.5% | -37.7% | +41.2% | -12.4% | +36.3% | +43.7% | -11.4% | +127.8% | +110.0% | +739.9% | +610.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.90 | 0.89 | 0.83 | 0.85 | 0.87 | 0.87 | 0.89 | 0.87 | 0.87 | 0.93 | 0.98 | 1.13 | 0.90 | 0.19 | 0.19 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 |
| — | +3.5% | +2.2% | -6.4% | -2.3% | -0.5% | -6.9% | -8.9% | -23.4% | -3.1% | +401.5% | +402.6% | +453.0% | +331.1% | -15.3% | -17.4% | -17.2% | +46.6% | +53.1% | +56.7% | +68.0% | |
| Debt / EBITDA | 3.22 | 15.23 | 22.79 | 12.71 | 16.65 | 11.22 | 12.43 | 10.88 | 8.81 | 8.95 | 10.12 | 9.20 | 7.80 | 12.04 | 2.50 | 2.27 | 3.38 | 3.28 | 3.71 | 3.40 | 3.39 |
| — | +35.7% | +83.3% | +16.9% | +88.9% | +25.4% | +22.8% | +18.2% | +13.0% | -25.7% | +305.0% | +306.1% | +130.8% | +266.7% | -32.6% | -33.3% | -0.4% | -13.7% | -1.8% | -51.3% | -47.8% | |
| Current Ratio | 4.02 | 2.40 | 3.85 | 4.02 | 3.12 | 3.29 | 2.95 | 3.07 | 3.43 | 3.52 | 2.18 | 2.17 | 2.10 | 1.53 | 3.86 | 3.99 | 3.76 | 3.64 | 3.19 | 3.06 | 3.10 |
| — | -27.2% | +30.4% | +30.8% | -9.2% | -6.6% | +35.8% | +41.5% | +63.1% | +130.3% | -43.6% | -45.5% | -44.0% | -57.9% | +21.1% | +30.1% | +21.3% | +45.8% | +34.9% | +22.9% | +8.4% | |
| Quick Ratio | 2.90 | 1.71 | 2.82 | 2.90 | 2.21 | 2.21 | 2.02 | 2.19 | 2.61 | 2.63 | 1.72 | 1.70 | 1.68 | 1.11 | 2.88 | 2.90 | 2.75 | 2.69 | 2.35 | 2.17 | 2.08 |
| — | -22.3% | +39.4% | +32.6% | -15.5% | -16.1% | +17.4% | +28.6% | +55.7% | +136.1% | -40.1% | -41.2% | -38.9% | -58.5% | +22.2% | +33.4% | +32.4% | +57.1% | +47.4% | +33.2% | +19.8% | |
| Interest Coverage | 5.85 | 6.79 | 2.53 | 5.81 | 4.42 | 7.26 | 5.91 | 7.84 | 8.12 | 6.84 | 6.49 | 5.37 | 5.64 | 10.11 | 85.34 | 79.14 | 40.92 | 59.31 | 82.78 | 162.68 | 72.43 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMPH stock.
Amphastar Pharmaceuticals, Inc.'s current P/E is 12.4x. The average P/E over the last 4 quarters is 18.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Amphastar Pharmaceuticals, Inc.'s current operating margin is 19.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Amphastar Pharmaceuticals, Inc.'s business trajectory between earnings reports.